Veteran Suicide Prevention Act
Sponsored By: Representative Garbarino, Andrew R. [R-NY-2]
In Committee
Summary
A mandated, data-driven review of veteran suicides tied to VA care and prescribing. This bill would require the Secretary of Veterans Affairs to review deaths by suicide among all veterans who received VA hospital care or medical services in the five years before their death and to publish a findings report with policy recommendations within 18 months of enactment.
Show full summary
- Veterans and families would get a public, detailed accounting of covered deaths, including total numbers, age, gender, race, combat or trauma history, and whether VA-prescribed medications were present during the five-year review window.
- VA clinicians and facilities would face scrutiny because the review must list medications found at death, flag drugs with black box or suicide-related warnings, summarize VA diagnoses that led to prescriptions, count concurrent VA prescriptions, and identify facilities with markedly high prescription and suicide rates.
- Policymakers and the public would receive the Secretary's analysis and recommendations within 30 days after the review is complete to guide possible actions to improve veteran safety and well-being.
Your PRIA Score
Personalized for You
How does this bill affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this bill and every other piece of legislation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Bill Overview
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
VA review of veteran suicides
If enacted, the Secretary of Veterans Affairs would review suicides of covered veterans who died in the five years before enactment. The VA would finish the review within 18 months after enactment. The review would report total deaths and a demographic summary by age, gender, and race. It would list medications prescribed to and found in those veterans, highlighting drugs with black box warnings, off‑label uses, psychotropic drugs, and drugs with suicide‑related warnings. The review would summarize VA medical diagnoses that led to those prescriptions and count cases of veterans on multiple VA‑prescribed medicines. It would report the share not taking any VA‑prescribed medicine and the share with combat or trauma histories (including military sexual trauma, traumatic brain injury, and PTSD). The VA would identify facilities with unusually high prescription or suicide rates, describe VA prescribing policies, note any patterns, and make recommendations. The Secretary would send the report to Congress and make it public within 30 days after completion.
Sponsors & CoSponsors
Sponsor
Garbarino, Andrew R. [R-NY-2]
NY • R
Cosponsors
Rep. Lawler, Michael [R-NY-17]
NY • R
Sponsored 12/18/2025
Rep. Neguse, Joe [D-CO-2]
CO • D
Sponsored 12/18/2025
Kean
NJ • R
Sponsored 12/18/2025
Davis (NC)
NC • D
Sponsored 12/18/2025
Himes
CT • D
Sponsored 12/18/2025
Rep. Owens, Burgess [R-UT-4]
UT • R
Sponsored 3/4/2026
Rep. Harder, Josh [D-CA-9]
CA • D
Sponsored 3/16/2026
McBride
DE • D
Sponsored 3/16/2026
Del. Radewagen, Aumua Amata Coleman [R-AS-At Large]
AS • R
Sponsored 3/16/2026
Rep. Hayes, Jahana [D-CT-5]
CT • D
Sponsored 3/25/2026
Rep. Kiggans, Jennifer A. [R-VA-2]
VA • R
Sponsored 4/21/2026
Rep. Goodlander, Maggie [D-NH-2]
NH • D
Sponsored 4/28/2026
Rep. Pappas, Chris [D-NH-1]
NH • D
Sponsored 5/12/2026
Rep. Fuller, Clay [R-GA-14]
GA • R
Sponsored 5/14/2026
Roll Call Votes
No roll call votes available for this bill.
View on Congress.gov